Blueprint Medicines (NASDAQ:BPMC) Price Target Raised to $119.00
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its target price boosted by Piper Sandler from $109.00 to $119.00 in a report published on Monday,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. Several other brokerages have also recently weighed in on BPMC. JPMorgan Chase & Co. started coverage on shares of […]
More Stories
Zelenskyy Says He Will Meet Trump on Sunday to Discuss Peace Plan
By Tom Ozimek Ukrainian President Volodymyr Zelenskyy said on Dec. 26 that he will meet President Donald Trump in Florida...
Death Penalty Possible for Suspect in DC Shooting After New Federal Charges
By Bill Pan Rahmanullah Lakanwal, the man accused of killing a National Guard member and severely wounding another in an...
US Dollar Poised for Largest Annual Decline Since 2003
By Andrew Moran While the so-called Santa Claus rally delivered year-end gains for stocks and precious metals, the U.S. dollar...
The Good News of Economic Growth
By Jeffrey A. Tucker The Trump administration received some very welcome news in the form of third-quarter economic growth. Even...
Taiwan Gets Dec. 25 Off for First Time in Over 2 Decades
By Lily Zhou Residents of Taiwan got Dec. 25 off for the first time in nearly 25 years after lawmakers...
5 Million Christmas Lights Illuminate 19th Century Ohio Grist Mill
By Jeff Louderback CLIFTON, Ohio—With one flip of a switch, 5 million lights transform one of the country’s largest remaining...